Mariangela Ciccarese

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Benefit of taxanes as adjuvant chemotherapy for early breast cancer

Emilio Bria, Cecilia Nisticò, Federica Cuppone et al. · Cancer · 2006 · 147 citations · Full text

Medicine, Oncology, Pharmacology +14

Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers

Monica Ruggeri, Eleonora Pagan, Vincenzo Bagnardi et al. · The Breast · 2019 · 117 citations

Medicine, Gynecology, Oncology +17

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer

Serena Di Cosimo, Andrea Alimonti, G. Ferretti et al. · Annals of Oncology · 2004 · 63 citations

Medicine, Gynecology, Oncology +14